New treatment reduces pathogenic IgG while preserving B‑cell function

Original title: “IMAVVY approved as first targeted therapy for wAIHA”

nipocalimab for warm autoimmune hemolytic anemia results from the phase 2 3 randomized double blind energy study

Original title: “Nipocalimab for warm autoimmune hemolytic anemia: results from the phase 2/3 randomized, double-blind ENERGY study.”

targeting type i interferon in lupus autoimmune haemolytic anaemia first report with anifrolumab

Original title: “Targeting type I interferon in lupus autoimmune haemolytic anaemia: first report with anifrolumab.”

french protocol for the diagnosis and management of autoimmune hemolytic anemia in adults

Original title: “French protocol for the diagnosis and management of autoimmune hemolytic anemia in adults.”

bone marrow pathology in cold agglutinin mediated autoimmune hemolytic anemia a study of 56 cases

Original title: “Bone Marrow Pathology in Cold Agglutinin-Mediated Autoimmune Hemolytic Anemia: A Study of 56 Cases.”

An incredible success story for CAR-T cell therapy. Car-T cell therapy is “borrowed” from cancer treatment. Image in Creative Commons. A 47-year-old woman in Germany had spent more than a decade battling three severe autoimmune diseases at once: autoimmune hemolytic anemia (AIHA), immune thrombocytopenia (ITP), and antiphospholipid syndrome (APS). The team turned to CAR-T cell therapy. For the last decade, this technology has gained praise as a cure for blood cancers like leukemia. ... Stay ahead with ZME Science and subscribe. Please check your inbox and confirm your subscription. Discarded Thymus glands offer new hope for people with autoimmune disease · New treatment boosts survival rates for lung cancer patients Fabian Müller at the University Hospital of Erlangen in Germany in 2025, she was “refractory,” a clinical word that often means “we have nothing left to try.” She required daily infusions of blood. But there was one silver lining. The common denominator in all three of her diseases was a rogue faction of B cells. Then, doctors decided to try an extreme solution, a reboot of her entire immune system. They used CAR-T cell therapy, a therapy that has shown great promise in cancer treatment.

Original title: “Revolutionary Therapy Cured Three "Incurable" Autoimmune Diseases in a Patient”

Prof Fabian Müller, who led the ... life”. Clinical trials were needed to learn how durable the therapy was and whether it would be effective for other autoimmune diseases, he said. Woman who had pioneering cancer treatment 18 years ago still in remission ... The woman had a rare, life-threatening ... Prof Fabian Müller, who led the team, said the speed and depth of the woman’s response was “remarkable” and the therapy had “significantly improved her quality of life”. Clinical trials were needed to learn how durable the therapy was and whether it would be effective for other autoimmune diseases, he said. Woman who had pioneering cancer treatment 18 years ago still in remission ... The woman had a rare, life-threatening blood disorder, autoimmune haemolytic anaemia (AIHA), whereby rogue immune defences destroy red blood cells. A person receiving CAR T-cell therapy. The treatment has proved gamechanging for certain cancers. Photograph: Lucy North/PA ... Treatment reset wayward immune system of patient with life-threatening conditions, say scientists, in a world first ... A woman who lived with three life-threatening autoimmune diseases for more than a decade has returned to a near-normal life after a cell therapy reset her wayward immune system. The other, known as antiphospholipid syndrome (APS), has an opposing effect and raises the risk of harmful blood clots. All three diseases were due to wayward B-cells which make infection-fighting antibodies. With no options left, the doctors offered a treatment known as CAR (chimeric antigen receptor) T-cell therapy, which has proved gamechanging for certain cancers. “The prolonged response off normal therapy suggests there has been an immune reset,” he said, though how long it would last remained unclear. Parker, who is leading CAR-T trials on lupus and related autoimmune conditions in Manchester, said: “There are many active trials currently recruiting across autoimmune conditions, including lupus, myositis, MS, systemic sclerosis, vasculitis, and some have already reported early results. Case reports don’t prove a treatment works for wider use, hence the need for trials.”

Original title: “Woman with three deadly diseases has ‘remarkable’ recovery after cell therapy | Immunology | The Guardian”

warm autoimmune hemolytic anemia in adults in latin america a scoping review

Original title: “Warm autoimmune hemolytic anemia in adults in Latin America: A scoping review.”

management of pregnancy induced autoimmune haemolytic anaemia with rituximab a case report and narrative review

Original title: “Management of pregnancy-induced autoimmune haemolytic anaemia with rituximab. A case report and narrative review.”

Sanofi’s rilzabrutinib wins FDA Breakthrough Therapy and Japan orphan status for warm autoimmune hemolytic anemia. Sanofi’s (SNY) rilzabrutinib has been granted breakthrough therapy designation in the United States and orphan drug status in Japan for treating warm autoimmune hemolytic anemia, the drugmaker said on Monday.

Original title: “Sanofi’s rilzabrutinib gains breakthrough therapy status in US, orphan drug designation in Japan (SNY:NASDAQ) | Seeking Alpha”

Sanofi’s rilzabrutinib wins FDA Breakthrough Therapy and Japan orphan status for warm autoimmune hemolytic anemia. Sanofi’s (SNY) rilzabrutinib has been granted breakthrough therapy designation in the United States and orphan drug status in Japan for treating warm autoimmune hemolytic anemia, the drugmaker said on Monday.

Original title: “Sanofi’s rilzabrutinib gains breakthrough therapy status in US, orphan drug designation in Japan (SNY:NASDAQ) | Seeking Alpha”

The US and Japan granted breakthrough therapy/orphan status to rilzabrutinib for wAIHA, a rare blood disorder marked by the destruction of red blood cells... These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the fact that product candidates if approved may not be commercially successf The US Food and Drug Administration (FDA) has granted a designation as breakthrough therapy to Wayrilz (rilzabrutinib), a novel oral, reversible Bruton’s tyrosine kinase (BTK) inhibitor, for the treatment of patients with warm autoimmune hemolytic anemia (wAIHA), a rare autoimmune disorder marked by the destruction of red blood cells. The Japanese Ministry of Health, Labour and Welfare has also provided rilzabrutinib an orphan designation for the same condition. Other than the approved ITP indications in the US, EU, and UAE, these uses of rilzabrutinib are investigational and have not been evaluated by any regulatory authority. The FDA previously granted rilzabrutinib orphan drug designation for autoimmune hemolytic anemia, as well as two other rare diseases, IgG4-related disease (IgG4-RD) and sickle cell disease (SCD). Sanofi’s rilzabrutinib designated breakthrough therapy in the US and orphan drug in Japan for the treatment of warm autoimmune hemolytic anemia · Rilzabrutinib is the first and only investigational BTKi for warm autoimmune hemolytic anemia to be designated Breakthrough Therapy by the FDA

Original title: “Press Release: Sanofi’s rilzabrutinib designated breakthrough therapy in the US and orphan drug in Japan for the treatment of warm autoimmune hemolytic anemia”